Followers | 0 |
Posts | 918 |
Boards Moderated | 0 |
Alias Born | 11/11/2017 |
Sunday, July 05, 2020 11:45:08 AM
Trial exclusion.
Exclusion Criteria:
Confirmed diagnosis of ARDS
Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
Known medical history of tuberculosis or a risk for tuberculosis exposure
Known history of hepatitis A, hepatitis B, hepatitis C or HIV infection
History of pulmonary alveolar proteinosis (PAP)
Requiring invasive mechanical ventilation upon hospitalization prior to randomization
Women of childbearing potential who are pregnant or breastfeeding
Known hypersensitivity to lenzilumab or any of its components
Use of anti-IL-6 therapy or any other potent immunomodulatory or immunosuppressive therapy or live vaccine within 8 weeks of randomization (corticosteroid use is permitted)
Use of GM-CSF agents (e.g., sargramostim) within prior 2 months of randomization
Expected survival < 24h in the opinion of the investigator
Patient > 85 years of age
Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the patient at unacceptably
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM